Press Kit

WhiteLab Genomics is a TechBio company using artificial intelligence to design the building blocks of genomic medicines. Its proprietary ALFRED platform designs viral and non-viral delivery vehicles and programmable genetic payloads, which are then experimentally validated and tested in vivo to identify candidates with the properties required for therapeutic development. Through this integrated approach, WhiteLab Genomics is building a portfolio of validated bio-assets that it advances independently and with pharmaceutical and biotechnology partners developing the next generation of genomic medicines. Founded in 2019, WhiteLab works with industrial and academic partners including Sanofi, Cytiva, the University of Massachusetts, the Vision Institute in Paris and the Paris Brain Institute, alongside additional collaborations with biotechnology companies. The company is part of Y-Combinator, Station F and Future4Care and is a French Tech 2030 laureate. WhiteLab Genomics has raised a $26 million Series B financing led by AVP, with participation from Yaday Health and Blast Club, alongside existing investors Omnes Capital and Debiopharm Innovation Fund. WhiteLab Genomics operates from Paris, Boston, and Montreal.

David Del Bourgo, CEO and Co-Founder